| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd115dec46c157d3739020ebd4d866b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0314c17f8ea3bab5fd7bba8cdda11ac2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-06013 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 |
| filingDate |
2016-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb72ae15783b637da55b53a323a67d96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39de5c1d1a288588b77c2661967ae2e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcba50464d1d41cc7752ff27d07c5d1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62c73b67a52ed3370a9775783b38532a |
| publicationDate |
2022-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2990370-C |
| titleOfInvention |
Hunter syndrome therapeutic agent and treatment method |
| abstract |
The present invention relates to a Hunter syndrome therapeutic agent and, more specifically, to a Hunter syndrome therapeutic agent, which can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less by containing a first composition to be intravenously injected and a second composition to be subcutaneously injected, while exhibiting a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience. The IV/SC co-injection method according to the present invention replaces the conventional once-a-week IV injection method, requiring a patient to visit the hospital once a week, with SC injections by which a predetermined number of times among IV inj ections can directly be made at home by a guardian of the patient. |
| priorityDate |
2015-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |